Boster Immunoleader

antibody

Anti-MEK7 Antibody

PA1922

100 ug/vial

200 USD

polyclonal

rabbit

human, mouse, rat

Anti-MEK7 Antibody

PA1922

Polyclonal

Rabbit IgG polyclonal antibody for Dual specificity mitogen-activated protein kinase kinase 7(MAP2K7) detection. Tested with WB in Human;Mouse;Rat.

200 USD

Rabbit IgG

100 ug/vial

Lyophilized

No cross reactivity with other proteins.

Reacts with: human, rat Predicted to work with: mouse

WB

Concentration: 0.1-0.5μg/ml; Tested Species: Human, Rat; Predicted Species: Mouse

WB: The detection limit for MAP2K7 is approximately 1ng/lane under reducing conditions. Tested Species: In-house tested species with positive results. Predicted Species: Species predicted to be fit for the product based on sequence similarities. Other applications have not been tested. Optimal dilutions should be determined by end users.

A synthetic peptide corresponding to a sequence at the N-terminus of human MEK7(24-40aa ARRRIDLNLDISPQRPR), identical to the related rat and mouse sequences.

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3.

Immunogen affinity purified.

Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

At -20˚C for one year. After reconstitution, at 4˚C for one month. It can also be aliquotted and stored frozen at -20˚C for a longer time. Avoid repeated freezing and thawing.

Boster provides a series of assays reacted with primary antibodies. Antibody can be supported by chemiluminescence kit EK1002 in WB.

MAP2K7(Mitogen-activated protein kinase kinase 7), also known as MAP kinase kinase 7, MAPKK7, JNKK2, PRKMK7 or MKK7, is an enzyme that in humans is encoded by the MAP2K7 gene. This protein is a member of the mitogen-activated protein kinase kinase family. The MKK7 protein exists as six different isoforms with three possible N-termini(alpha, beta, and gamma isoforms) and two possible C-termini(1 and 2 isoforms). Schramek et al.(2011) showed that the doxorubicin-mediated DNA damage response in human A549 lung carcinoma cells caused rapid phosphorylation and upregulation of p53(TP53). MKK7 knockdown reduced p53 phosphorylation, delayed p53 upregulation, and interfered with cell cycle arrest at G2/M. MKK7 was activated in primary lung tumors, and tumors with a p53 mutation showed even higher MKK7 phosphorylation. Schramek et al.(2011) concluded that MKK7 exerts its tumor suppressive function through p53.

1. Lu, X., Nemoto, S., Lin, A. Identification of c-jun NH(2)-terminal protein kinase (JNK)-activating kinase 2 as an activator of JNK but not p38. J. Biol. Chem. 272: 24751-24754, 1997. 2. Schramek, D., Kotsinas, A., Meixner, A., Wada, T., Elling, U., Pospisilik, J. A., Neely, G. G., Zwick, R.-H., Sigl, V., Forni, G., Serrano, M., Gorgoulis, V. G., Penninger, J. M. The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression. Nature Genet. 43: 212-219, 2011. 3. Wu, Z., Wu, J., Jacinto, E., Karin, M. Molecular cloning and characterization of human JNKK2, a novel jun NH(2)-terminal kinase-specific kinase. Molec. Cell. Biol. 17: 7407-7416, 1997.

MAP2K7

Dual specificity mitogen-activated protein kinase kinase 7

mitogen-activated protein kinase kinase 7

c Jun N terminal kinase kinase 2 antibody c-Jun N-terminal kinase kinase 2 antibody Dual specificity mitogen activated protein kinase kinase 7 antibody Dual specificity mitogen-activated protein kinase kinase 7 antibody JNK activating kinase 2 antibody JNK kinase 2 antibody JNK-activating kinase 2 antibody JNKK 2 antibody Jnkk-2 antibody Jnkk2 antibody MAP kinase kinase 7 antibody MAP2K 7 antibody MAP2K7 antibody MAPK/ERK kinase 7 antibody MAPKK 7 antibody MAPKK-7 antibody MAPKK7 antibody MEK 7 antibody Mitogen activated protein kinase kinase 7 antibody MKK 7 antibody MKK-7 antibody MKK7 antibody MP2K7_HUMAN antibody PRKMK 7 antibody PRKMK-7 antibody PRKMK7 antibody Protein kinase mitogen activated kinase 7 antibody Sek 2 antibody Sek-2 antibody Sek2 antibody SKK4 antibody

O14733